Compare MC & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MC | IOVA |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 968.6M |
| IPO Year | 2014 | N/A |
| Metric | MC | IOVA |
|---|---|---|
| Price | $69.20 | $2.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 12 |
| Target Price | ★ $73.50 | $10.36 |
| AVG Volume (30 Days) | 852.7K | ★ 9.8M |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.73% | N/A |
| EPS Growth | ★ 446.16 | N/A |
| EPS | ★ 3.17 | N/A |
| Revenue | ★ $1,467,580,000.00 | $250,425,000.00 |
| Revenue This Year | $27.25 | $60.94 |
| Revenue Next Year | $17.11 | $60.85 |
| P/E Ratio | $22.00 | ★ N/A |
| Revenue Growth | 51.19 | ★ 175.62 |
| 52 Week Low | $47.00 | $1.64 |
| 52 Week High | $82.89 | $8.56 |
| Indicator | MC | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 61.66 | 46.56 |
| Support Level | $62.77 | $2.18 |
| Resistance Level | $72.26 | $2.32 |
| Average True Range (ATR) | 2.17 | 0.12 |
| MACD | 0.89 | -0.01 |
| Stochastic Oscillator | 74.16 | 18.11 |
Moelis & Co is an independent investment bank that provides strategic and financial advice to a diverse client base, including corporations, financial sponsors, governments, and sovereign wealth funds. The company assists its clients in achieving their strategic goals by offering comprehensive, globally integrated financial advisory services across all industry sectors. It also advises clients on their critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. it generates revenue from advisory transactions. The firm derives a majority of its revenue from the United States followed by Europe and the rest of the World.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.